AOD-9604: The Growth Hormone Fragment for Fat Loss Research
The search for targeted fat-loss agents has long driven pharmaceutical research, and few peptides illustrate the promise — and complexity — of that pursuit quite like AOD-9604. This modified fragment of human growth hormone (hGH) was designed to isolate the lipolytic (fat-burning) properties of GH without triggering its diabetogenic or growth-promoting effects. While it gained mainstream attention through anti-aging and wellness communities, the underlying science tells a more nuanced story of clever molecular engineering, encouraging preclinical data, and clinical trials that left researchers with as many questions as answers.
What Is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to amino acids 177–191 of human growth hormone, the C-terminal fragment of the protein. The peptide is further stabilized by the addition of a tyrosine residue at its N-terminus, yielding a 16-amino-acid sequence with a molecular weight of approximately 1817.12 Da.
The original concept emerged from research at Monash University in Australia, led by Frank Ng and colleagues, who demonstrated that this small region of the GH molecule could replicate its fat-metabolizing activity in animal models. The key innovation was severing the lipolytic signal from the broader anabolic and metabolic cascade triggered by full-length growth hormone.
Unlike intact GH, AOD-9604 does not bind the canonical growth hormone receptor (GHR) in a way that stimulates IGF-1 production. This distinction is critical — it means the peptide was designed to promote fat loss without the hyperglycemia, insulin resistance, or acromegalic tissue growth associated with supraphysiological GH exposure.
Mechanism of Action
AOD-9604 appears to act through a distinct signaling pathway that is related to, but not identical to, the full GH receptor cascade. Early research by Ng et al., 2000 showed that the hGH 177–191 fragment stimulated lipolysis in adipose tissue from both obese and lean mice, with potency comparable to intact human growth hormone.
The proposed mechanism involves stimulation of beta-3 adrenergic receptor pathways and direct activation of lipolysis in adipocytes. Importantly, studies found that AOD-9604 enhanced fat oxidation without altering food intake or lean body mass in animal models, suggesting a relatively targeted metabolic effect.
Research published in *The Journal of Endocrinology* further showed that the fragment not only stimulated fat breakdown but also appeared to inhibit lipogenesis — the formation of new fatty acids from non-fat substrates. This dual action (pro-lipolytic and anti-lipogenic) set AOD-9604 apart from many single-mechanism anti-obesity compounds.
A key piece of the safety profile came from studies demonstrating that AOD-9604 did not raise serum IGF-1 levels or impair glucose tolerance at effective doses. Heffernan et al., 2001 showed that chronic administration in obese mice reduced body weight gain without the diabetogenic effects observed with full-length GH treatment.
Preclinical Evidence
The preclinical data for AOD-9604 was genuinely promising. In obese (ob/ob) mice, the peptide produced dose-dependent reductions in body fat over treatment periods of several weeks. These findings were consistent across multiple studies from the Monash University group.
Key preclinical findings include:
Ng et al., 2001 also demonstrated that the mechanism required an intact disulfide loop within the 177–191 region, confirming that the peptide's activity was structure-dependent rather than a nonspecific artifact.
Clinical Trial History
Based on strong preclinical results, AOD-9604 advanced into human clinical trials under the Australian pharmaceutical company Metabolic Pharmaceuticals (later renamed Calzada Ltd). The clinical program ultimately became one of the most discussed — and debated — chapters in peptide obesity research.
A Phase 2a clinical trial involved 300 obese participants and evaluated oral formulations of AOD-9604 at doses of 1 mg, 5 mg, and 20 mg daily over 12 weeks. Results presented at the 2004 American Diabetes Association meeting were mixed: while there was a trend toward greater weight loss in treatment groups, particularly at the 1 mg dose, the study did not achieve its primary endpoint of statistically significant weight reduction versus placebo across all groups.
The safety data, however, was reassuring. AOD-9604 was generally well tolerated with no serious adverse events attributed to treatment. Crucially, no changes in IGF-1, glucose metabolism, or insulin sensitivity were observed, confirming in humans what preclinical work had predicted.
A subsequent Phase 2b study was conducted but similarly failed to demonstrate robust efficacy at the doses and formulations tested. Metabolic Pharmaceuticals ultimately ceased development of AOD-9604 as an oral anti-obesity drug, citing the difficulty of achieving consistent bioavailability with oral peptide delivery — a challenge that continues to plague the field.
Regulatory Status and Current Research Landscape
AOD-9604 received Generally Recognized as Safe (GRAS) status from the U.S. FDA in 2014 for use as a food ingredient, specifically as a component of certain functional food products marketed by a company that licensed the technology. This status applies only to a specific use case and does not constitute approval as a drug or therapeutic agent.
The peptide has also been explored for musculoskeletal applications. Metabolic Pharmaceuticals and its successor entities investigated AOD-9604 for osteoarthritis and cartilage repair, leveraging early evidence that the GH fragment might stimulate chondrocyte proliferation. An intra-articular formulation was studied, though large-scale clinical validation remains limited.
In the sports world, AOD-9604 was added to the World Anti-Doping Agency (WADA) prohibited list in 2023 under the category of growth hormone fragments, reflecting its growing use among athletes seeking body composition advantages.
Limitations and Open Questions
Despite its appealing mechanism, several significant limitations temper enthusiasm for AOD-9604:
It is also worth noting that the research-grade peptide market for AOD-9604 is unregulated, and product purity and identity can vary substantially between suppliers — a concern for any researcher working with commercially sourced material.
Comparison to Related Approaches
AOD-9604 occupies a unique niche: it is designed to capture one specific function of a pleiotropic hormone. This approach contrasts sharply with full-length growth hormone (191 amino acids), which activates the GH receptor broadly, raises IGF-1, and carries metabolic risks at supraphysiological doses.
It also differs from GH-releasing peptides (GHRPs) and growth hormone secretagogues, which amplify endogenous GH secretion rather than mimicking a single downstream effect. The fragment approach of AOD-9604 is more targeted in theory, though arguably less potent in practice.